サンプル依頼リスト カート
  • English
  • Korean
表紙：アッシャー症候群治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1345385

アッシャー症候群治療の世界市場-2023年～2030年

Global Usher Syndrome Treatment Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
アッシャー症候群治療の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のアッシャー症候群治療市場は、2022年に16億米ドルに達し、2023-2030年の予測期間中にCAGR 4.6％で成長し、2030年には23億米ドルに達すると予測されています。

世界のアッシャー症候群治療市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって大きな成長と変貌を遂げてきました。アッシャー症候群は網膜色素変性症（RP）の一種で、難聴を伴う。ミシガン大学保健学部によると、アッシャー症候群は遺伝性難聴の約10％の原因であり、難聴は出生時または出生後すぐに発症します。

さらに、現在のところ、この症候群を治療する方法はないが、アッシャー症候群を管理するために使用される明確な方法があります。アッシャー症候群の管理には、補聴器、視覚補助具、人工内耳、ビタミンAサプリメント、言語療法、理学療法、作業療法などが一般的です。補聴器は、アッシャー症候群の管理に最も一般的に使用されています。

補聴器が最大の市場シェアを占めると予想されます。同様に、北米がアッシャー症候群治療市場を独占し、予測期間中最大の市場シェアを獲得すると予想されています。クリーブランド・クリニック機構によると、アッシャー症候群の子供は10万人あたり4～17人で、聴覚障害児全体の3～6％がこの病気です。この病気を受け継ぐには、両親の両方がアッシャー症候群の原因となる遺伝子を持っていなければならないです。

アッシャー症候群の有病率の増加、アッシャー症候群とその治療法に関する認知度の向上、新規治療薬の治験と規制当局による承認の増加、補聴器と人工内耳の進歩が、予測期間中に世界のアッシャー症候群治療市場の成長を促進すると予想される主な要因です。

市場力学

アッシャー症候群治療市場の成長を牽引すると期待される新規治療薬の治験と規制当局による承認の増加

現在進行中の治験と規制当局の承認は、新規治療薬の開発に重要な役割を果たしており、予測期間中の市場シェアを押し上げると期待されています。治験は、薬剤、医療機器、遺伝子治療、その他の介入を含む新しいアッシャー症候群治療アプローチの安全性と有効性を試験するために非常に不可欠です。アッシャー症候群の効果的な治療法を見つけるために、より多くの研究開発が行われており、治験の増加は、この稀な遺伝性疾患への取り組みに対する関心の高まりを表しています。

例えば、2023年4月10日、ダラスに本社を置くNacuity社は、経口抗酸化療法に関する第I/II相治験をオーストラリアで開始しました。この試験はアッシャー症候群の患者を対象としています。The Foundation Fighting Blindness（失明と闘う財団）は、網膜色素変性症、アッシャー症候群、および関連疾患に対する有望な新薬を開発するため、最大750万米ドルを投資しています。N-アセチルシステイン-アミド（NACA）として知られるこの分子は、網膜細胞を酸化ストレスから保護することで、視力低下を遅らせるように設計されています。

FDAのような規制当局の承認もまた、アッシャー症候群をより良く管理するための新しい治療薬の開発において重要な役割を果たしています。新規治療薬が規制当局の承認を受けるということは、その治療薬が安全性と有効性に関する厳格な基準を満たしていることを意味します。このような承認は、患者が新しい治療薬にアクセスするために重要であるだけでなく、アッシャー症候群治療の分野で投資を呼び込み、さらなる研究を促進するためにも重要です。

認知度の向上もアッシャー症候群治療市場の成長を促進すると予想される

アッシャー症候群に関する認知度の向上は、予測期間にわたってアッシャー症候群治療市場を牽引します。啓発キャンペーンは、アッシャー症候群の症状や初期徴候について医療専門家や一般市民を教育するのに役立ち、早期管理に役立つ可能性があります。早期発見・診断により、タイムリーな介入が可能となり、病気の進行を遅らせたり、治療効果を向上させたりできる可能性があります。

例えば、アッシャー症候群連合によると、9月の第3土曜日は「アッシャー症候群啓発デー」です。アッシャー症候群啓発デーは、難聴と失明を併発する最も一般的な遺伝的原因に注意を喚起することを目的としています。世界中で認知度を高めることで、アッシャー症候群の患者をつなぎ、治療や治癒に向けた調査を加速させることができます。

啓発キャンペーンや患者支援団体は、アッシャー症候群の早期発見、診断、管理に専念しています。これらのグループは、認知度を高め、罹患者とその家族に支援を提供し、研究と治療開発を加速させるイニシアチブを推進する上で重要な役割を果たしています。強力なアドボカシー活動は、研究者や医療上の利害関係者の注目を集め、共同研究の増加と治療開発の進展につながります。

アッシャー症候群治療薬への資金不足が市場成長の妨げに

アッシャー症候群治療薬に対する資金不足は、予測期間における世界のアッシャー症候群治療薬市場の妨げとなります。研究開発のための資金不足は、アッシャー症候群治療のための新しい治療アプローチの発見に支障をきたす可能性があります。研究開発投資のための資金不足は、革新的な治療法の開発を減少させ、アッシャー症候群患者が利用できる治療法の選択肢を制限し、この分野の進歩を妨げる可能性があります。

治験も新規治療において重要な役割を果たすが、資金不足は治験の実施にも影響を与える可能性があります。治験には、参加者の募集と登録、試験の実施、結果の分析に資金が必要です。このようなヘルスケア支出の減少は、実施される治験の減少につながり、アッシャー症候群患者が、より良い病気の管理につながる研究に参加する機会を制限することになります。

高い治療費も市場の成長を妨げる

高い治療費は、予測期間中の市場成長を妨げる可能性があります。また、このような高額な治療費は、保険適用範囲、特に限られた財源のために、人口のかなりの部分がタイムリーな治療を受けられなくします。このようなアクセス制限により、患者数が減少し、その結果、コスト抑制のために治療需要が低下する可能性があります。

例えば、アッシャー症候群連合によると、遺伝子検査の費用と納期は、検査機関や検査方法によって異なります。アッシャー検査の費用は500米ドル程度です。より正確で詳細な検査には、2,000～5,000米ドルかかる場合もあります。結果が出るまでの一般的な期間は8～12週間で、治療にも多くの費用がかかります。

医療提供者は、特に、より手頃な代替治療がある場合、高額な費用のかかる治療を推奨したり、実施したりすることをためらうかもしれないです。その結果、利用可能な治療法の採用が減少し、市場成長の妨げになる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規治療薬の治験と承認取得の増加
      • 認知度の向上
    • 抑制要因
      • 不十分な資金と投資
      • 高い治療費
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 疾患タイプ別

  • タイプ-1
  • タイプ-2
  • タイプ-3

第8章 治療タイプ別

  • 補聴器
  • 人工内耳
  • 視覚補助
  • 言語療法
  • 理学療法
  • 作業療法
  • ビタミンAサプリメント
  • その他

第9章 エンドユーザー別

  • 病院
  • 眼科クリニック
  • 耳鼻咽喉科クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • MED-EL
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Audina Hearing Instruments, Inc.
  • Sonova
  • Earsmate
  • Ototronix Diagnostics
  • Rion Co. Ltd.
  • Cochlear Ltd
  • Tobii Dynavox US
  • Enhanced Vision
  • Nurotron Biotechnology Co. Ltd

第13章 付録

目次
Product Code: PH6749

Market Overview

Global Usher Syndrome Treatment Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.3 billion by 2030, growing with a CAGR of 4.6% during the forecast period 2023-2030.

The global usher syndrome treatment market has experienced significant growth and transformations over the years, with various factors influencing its dynamics. Usher syndrome is a form of retinitis pigmentosa (RP), with associated deafness. According to the University of Michigan Health, usher syndrome is the cause of approximately 10% of all hereditary deafness, with deafness existing at birth or developing soon afterward.

Moreover, currently, there is no cure for the syndrome, but there are distinct ways are used to manage the usher syndrome. The management of usher syndrome commonly includes hearing aids, vision aids, cochlear implants, vitamin A supplements, speech therapy, physical therapy, occupational therapy, and others. Hearing aids are most commonly used for the management of usher syndrome.

Hearing aids are expected to account for the largest market share. Similarly, North America is expected to dominate the usher syndrome treatment market, capturing the largest market share of over the forecast period. According to the Cleveland Clinic Organization, about 4 to 17 per 100,000 children are born with usher syndrome and it's the cause of deafness in 3% to 6% of all children who are deaf. To inherit the disease, both of the parents must carry the gene that causes usher syndrome.

Owing to the increasing prevalence of usher syndrome, increasing awareness about the usher syndrome and their treatments, rising clinical trials and regulatory approvals for novel therapeutics, and advancements in hearing aids and cochlear implants are the major factors expected to drive the growth of the global usher syndrome treatment market over the forecast period.

Market Dynamics

Rising Clinical Trials and Regulatory Approvals for Novel Therapeutics Expected to Drive the Growth of the Usher Syndrome Treatment Market

The ongoing clinical trials and regulatory approvals plays an important role in the development of novel therapeutics, which is expected to drive the market share over the forecast period. Clinical trials are very essential for testing the safety and efficacy of new usher syndrome therapeutic approaches, including drugs, medical devices, gene therapies, and other interventions. As more research and development efforts are focused on finding effective treatments for Usher syndrome, an increase in clinical trials indicates a growing interest in addressing this rare genetic disorder.

For instance, on April 10, 2023, Dallas-based Nacuity launched a Phase I/II clinical trial in Australia for its oral antioxidant therapy. The trial is for people with Usher syndrome. The Foundation Fighting Blindness is investing up to $7.5 million to advance the promising, emerging drug for retinitis pigmentosa, Usher syndrome, and related conditions. Known as N-acetylcysteine-amide (NACA), the molecule is designed to slow vision loss by protecting retinal cells from oxidative stress.

Regulatory approvals such as FDA also plays a crucial role in the development of new therapeutics for the better management of the usher syndrome. When a novel therapeutic receives regulatory approval, it signifies that the treatment has met rigorous standards for safety and effectiveness. Such approvals are not only important for patient access to new therapeutics but also for attracting investment and fostering further research in the field of usher syndrome treatment.

Increasing Awareness Also Expected to Drives the Growth of the Usher Syndrome Treatment Market

The increasing awareness about usher syndrome drives the usher syndrome treatment market over the forecast period. The awareness campaigns helps to educate healthcare professionals and the public about the symptoms and early signs of usher syndrome, which may helps in early management. Early detection and diagnosis allows for timely intervention, which can potentially slow the progression of the disease and improve the effectiveness of treatments.

For instance, according to the usher syndrome coalition, the third Saturday in September is Usher Syndrome Awareness Day. Usher Syndrome Awareness Day seeks to bring attention to the most common genetic cause of combined deafness and blindness. By raising awareness around the world, able to connect those living with Usher syndrome and accelerate research towards treatments and a cure.

The awareness campaigns and patient advocacy groups are dedicated to usher syndrome early detection, diagnosis, and management. These groups play a vital role in raising awareness, providing support to affected individuals and their families, and driving initiatives to accelerate research and treatment development. Strong advocacy efforts can attract attention from researchers and healthcare stakeholders, leading to increased collaboration and progress in therapeutic developments.

Insufficient Funding for Usher Syndrome Therapeutics Hampers the Market Growth

The lack of funding for usher syndrome therapeutics hampers the global usher syndrome treatment market over the forecast period. Insufficient funding for research and development can disrupt the discovery of new therapeutic approaches for usher syndrome treatment. Insufficient funding for R&D investments may result in fewer innovative treatments being developed, limiting the treatment options available to individuals with usher syndrome and hindering advancements in the field.

Clinical trials also plays a crucial role in novel therapeutics, the lack of funding may also impact the conducting of clinical trials. Clinical trials require funding to recruit and enroll participants, conduct the trials, and analyze the results. This reduced healthcare expenditure can lead to fewer clinical trials being conducted, limiting the opportunities for individuals with usher syndrome to participate in research that could lead to better management of the disease.

High Treatment Costs Also Hampers the Growth of the Market

The high treatment costs can hamper the market growth over the forecast period. And these high treatment costs make timely treatments inaccessible to a significant portion of the population due to the limited insurance coverage, and especially those limited financial resources. This limited access could result in a smaller patient pool and, consequently, lower demand for treatments due to the cost restraints.

For instance, according to the usher syndrome coalition, the cost and turn-around time of a genetic test may vary depending on the lab and the methods used for testing. Some usher screens cost around $500. More accurate and detailed testing may cost between $2000-$5000. A typical range of time to get the results might be 8-12 weeks and the treatment also costs much.

Healthcare providers might be hesitant to recommend or administer treatments with high costs, especially if there are alternative treatments available that are more affordable. This could result in reduced adoption of the available treatments which further leads to the hampering market growth.

Segment Analysis

The global usher syndrome treatment market is segmented based on disease type, treatment type, end-user, and region.

The Hearing Aids from the Treatment Segment Accounted for Approximately 37.6% of the Market Share

There is no specific treatment or cure for usher syndrome, but hearing aids plays a significant role in the management of hearing loss in usher syndrome patients. Children with type 3 usher syndrome often develop hearing loss by adolescence, requiring hearing aids by mid-to-late adulthood for the management of hearing loss. Hearing aids play a role by amplifying sounds, making them louder and easier for individuals with hearing loss to perceive. This can improve their ability to communicate and engage with their surroundings.

For instance, on August 17, 2022, Lucid Hearing, LLC, a market leader and global provider of advanced hearing technology and audio solutions, commends the Food and Drug Administration (FDA) for its efforts to give Americans expanded access to hearing solutions. The ruling as finalized by the FDA creates a new over-the-counter (OTC) category which allows hearing aids to be sold directly online and in stores to consumers without requiring a medical visit, audiogram test, or prescription.

Moreover, hearing aids helps usher syndrome patients by restoring or enhancing hearing and hearing aids can also improve an individual's overall quality of life with better and enhanced management of hearing loss. They can participate more fully in conversations, social interactions, and daily activities by using hearing aids. Early identification and fitting of hearing aids for individuals with Usher syndrome can contribute to better hearing, speech and language development in children.

Geographical Penetration

North America Accounted for Approximately 41.8% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Strong Presence of Major Players

North America region holds the largest market share over the forecast period especially due to the advanced and well-established healthcare infrastructure and the strong presence of major players in the region. North America, especially in the United States and Canada, is well-known for its advanced healthcare infrastructure which includes hospitals, ophthalmic clinics, ENT clinics, and others, which facilitates early detection, diagnosis, and better management of usher syndrome. This encompasses market dominance in the region.

Moreover, many key global major players in the region including pharmaceutical companies, organizations, and research institutions facilitate conducting clinical trials and research activities which enhance innovative treatment options for better management. Their strong presence can contribute to the growth and expansion of the market, as they bring expertise, resources, funding, and investments into the region, leading to market dominance in the region.

For instance, on October 18, 2022, Eli Lilly and Company and Akouos, Inc. announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss including multiple inner ear conditions such as AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision.

Competitive Landscape

The major global players in the usher syndrome treatment market include MED-EL, Audina Hearing Instruments, Inc., Sonova, Earsmate, Ototronix Diagnostics, Rion Co. Ltd., Cochlear Ltd, Tobii Dynavox US, Enhanced Vision, and Nurotron Biotechnology Co. Ltd among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created many challenges for the healthcare industries worldwide, including the global usher syndrome treatment market. During the pandemic, most of the countries faced more challenges due to the lockdown restrictions, supply chain disruptions, and reduced research activities and clinical trials are seen, which significantly impacted the global market.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting on developing the innovative treatment options. Major pharmaceutical industries faced challenges in conducting clinical trials for the usher syndrome treatment due to redirection towards COVID-19 pandemic treatment.

The COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as hearing aids, visual aids, and other medical devices used in the treatment of usher syndrome. Movement restrictions and border closures delayed shipments and caused production delays. Additionally, some countries faced shortages of raw materials due to disruptions in their supply chain networks.

With the outbreak of the pandemic, telecommunication has improves and helped in many ways. Telecommunication is a positive impact that helps the patients for timely consultation for the rural people. However, these measures explained the impact of the COVID-19 pandemic on global usher syndrome treatment market.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global usher syndrome treatment market. Many clinical trials and research activities are temporarily disrupted which is directly impacted the development of novel therapeutics for the treatment of usher syndrome.

The conflict has less impact mainly due to the low prevalence in the region and the absence of key market players in this region. The conflict also affected the supply chains and transportation of raw materials and medical devices which are used in the treatment of the usher syndrome.

By Disease Type

  • Type 1
  • Type 2
  • Type 3

By Treatment Type

  • Hearing Aids
  • Cochlear Implants
  • Vision Aids
  • Speech Therapy
  • Physical Therapy
  • Occupational Therapy
  • Vitamin A Supplements
  • Others

By End-User

  • Hospitals
  • Ophthalmic Clinics
  • ENT Clinics
  • Others

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

UK

France

Italy

Spain

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • On June 06, 2023, AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, announced the closing of a €61 million Series A financing. The financing was co-led by US biotechnology venture creation firm Atlas Venture and European life sciences venture capital investment firm Forbion, with participation from Longwood Fund and the Company's founding investor Sofinnova Partners through its Sofinnova Telethon Fund. The company is validating the platforms in two lead programs, Usher Syndrome Type 1 B associated retinitis pigmentosa (Usher1B), using dual hybrid, and Stargardt disease, using AAV intein.
  • On September 13, 2022, Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other diseases caused by oxidative stress, and Arctic Therapeutics International, precision-based drug development and diagnostic testing company using genetic and genealogy information to guide therapeutic development, announced the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland. NPI-001 has been granted orphan designation by the U.S. Food and Drug Administration for the treatment of retinitis pigmentosa in Usher Syndrome and is currently being evaluated in a Phase 1/2 clinical trial for Usher Syndrome
  • On October 31, 2022, Platform technology company Replay launched Eudora, a gene therapy company targeting genetic diseases of the retina. Eudora will utilize Replay's high payload capacity herpes simplex virus (HSV) vector to deliver gene therapy payloads, the company announced. Replay plans to launch four companies using this technology, although Eudora is the first to launch. The other three will focus on brain, skin, and muscle diseases. Eudora is initially focused on retinitis pigmentosa, Stargardt disease, and Usher syndrome type 1B.

DataM Intelligence Opinion:

According to the DataM Intelligence, the usher syndrome treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing demand for novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment by controlling hearing loss and vision loss. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global usher syndrome treatment market in the upcoming years.

Why Purchase the Report?

  • To visualize the global usher syndrome treatment market segmentation based on disease type, treatment type, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of usher syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global usher syndrome treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Clinical Trials and Regulatory Approvals for Novel Therapeutics
      • 4.1.1.2. Increasing Awareness
    • 4.1.2. Restraints
      • 4.1.2.1. Insufficient Funding and Investments
      • 4.1.2.2. High Treatment Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Type-1 *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Type-2
  • 7.4. Type-3

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Hearing Aids *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cochlear Implants
  • 8.4. Vision Aids
  • 8.5. Speech Therapy
  • 8.6. Physical Therapy
  • 8.7. Occupational Therapy
  • 8.8. Vitamin A Supplements
  • 8.9. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ophthalmic Clinics
  • 9.4. ENT Clinics
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. MED-EL *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Audina Hearing Instruments, Inc.
  • 12.3. Sonova
  • 12.4. Earsmate
  • 12.5. Ototronix Diagnostics
  • 12.6. Rion Co. Ltd.
  • 12.7. Cochlear Ltd
  • 12.8. Tobii Dynavox US
  • 12.9. Enhanced Vision
  • 12.10. Nurotron Biotechnology Co. Ltd

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us